Inogen, Inc. (NASDAQ:INGN) Short Interest Down 11.4% in October

Inogen, Inc. (NASDAQ:INGN) was the recipient of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 826,300 shares, a decrease of 11.4% from the October 15th total of 932,600 shares. Based on an average daily volume of 190,100 shares, the short-interest ratio is presently 4.3 days.

Inogen Stock Down 5.3 %

NASDAQ:INGN opened at $9.52 on Tuesday. Inogen has a 52 week low of $4.93 and a 52 week high of $13.33. The stock has a market capitalization of $226.75 million, a PE ratio of -4.43 and a beta of 1.04. The stock’s 50-day moving average price is $9.82 and its 200-day moving average price is $9.55.

Analysts Set New Price Targets

INGN has been the topic of a number of research reports. Needham & Company LLC reissued a “hold” rating on shares of Inogen in a report on Friday, November 8th. StockNews.com upgraded Inogen from a “hold” rating to a “buy” rating in a research note on Tuesday, November 12th.

Institutional Investors Weigh In On Inogen

Several institutional investors have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its holdings in Inogen by 5.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,868 shares of the medical technology company’s stock worth $193,000 after buying an additional 1,188 shares during the last quarter. Meeder Asset Management Inc. acquired a new stake in Inogen in the 2nd quarter worth about $30,000. BNP Paribas Financial Markets boosted its holdings in Inogen by 13.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 42,137 shares of the medical technology company’s stock worth $409,000 after buying an additional 5,131 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Inogen by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 554,191 shares of the medical technology company’s stock worth $5,377,000 after buying an additional 5,921 shares during the last quarter. Finally, Quarry LP acquired a new stake in Inogen in the 3rd quarter worth about $59,000. 89.94% of the stock is currently owned by institutional investors and hedge funds.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.